| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 667 1 |
| Ultima descărcare din IBN: 2023-05-03 12:05 |
 SM ISO690:2012DUMBRAVA, Vlada-Tatiana, , , , , , , , , COJUHARI, Maria, DELI, M.. Evaluarea tratamentului antiviral la pacienţii cu ciroze hepatice de etiologie virală C şi D. In: Sănătate Publică, Economie şi Management în Medicină , 2013, nr. 5(50), pp. 118-122. ISSN 1729-8687. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Sănătate Publică, Economie şi Management în Medicină | ||||||
| Numărul 5(50) / 2013 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
| Pag. 118-122 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Study group: 49 patients, 17 (34.69%) women and 32 (65.31%) men with hepatic viral cirrhosis, Child-Pugh stage A: 24 – D viral etiology and 25 – viral C genesis. Average age: 44.41 ± 0.4 years in women and 47.59 ± 0.6 years in men. Purpose: evaluation of the antiviral treatment response at 12 weeks and 24 weeks after initiation and assessment of laboratory results during antiviral therapy in patients with liver cirrhosis C and D. In patients with liver cirrhosis HDV, treated with Peg-INF undetectable viral load was achieved at 12 weeks in 28% cases and after 24 weeks of treatment it is observed in 25% cases. In the group of patients with liver cirrhosis HCV, treated with Peg-INF + Ribabirină – 12 weeks of treatment – 75% of patients responded positively: 48% achieved complete EVR and 24% – EVR part. Evaluation of patients at 24 weeks of treatment show a positive virologic response in 56% cases. In patients with liver cirrhosis HCV and HDV, where the virological response was absent, more severe and early complications of antiviral therapy are observed: the blood count shows anemia, major leukopenia and thrombocytopenia. |
||||||
| Cuvinte-cheie liver cirrhosis, antiviral treatment, sustained virological response, unidentifi ed viremia, цирроз печени, противовирусное лечение, вирусологический ответ, авиремия |
||||||
|
Dublin Core Export
<?xml version='1.0' encoding='utf-8'?> <oai_dc:dc xmlns:dc='http://purl.org/dc/elements/1.1/' xmlns:oai_dc='http://www.openarchives.org/OAI/2.0/oai_dc/' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xsi:schemaLocation='http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd'> <dc:creator>Dumbrava, V.A.</dc:creator> <dc:creator>Лупашко, ..</dc:creator> <dc:creator>Таран, .</dc:creator> <dc:creator>Тофан-Скутару, .</dc:creator> <dc:creator>Тофан-Скутару, .</dc:creator> <dc:creator>Cojuhari, M.</dc:creator> <dc:creator>Deli, M.</dc:creator> <dc:date>2013-10-01</dc:date> <dc:description xml:lang='en'><p>Study group: 49 patients, 17 (34.69%) women and 32 (65.31%) men with hepatic viral cirrhosis, Child-Pugh stage A: 24 – D viral etiology and 25 – viral C genesis. Average age: 44.41 ± 0.4 years in women and 47.59 ± 0.6 years in men. Purpose: evaluation of the antiviral treatment response at 12 weeks and 24 weeks after initiation and assessment of laboratory results during antiviral therapy in patients with liver cirrhosis C and D. In patients with liver cirrhosis HDV, treated with Peg-INF undetectable viral load was achieved at 12 weeks in 28% cases and after 24 weeks of treatment it is observed in 25% cases. In the group of patients with liver cirrhosis HCV, treated with Peg-INF + Ribabirină – 12 weeks of treatment – 75% of patients responded positively: 48% achieved complete EVR and 24% – EVR part. Evaluation of patients at 24 weeks of treatment show a positive virologic response in 56% cases. In patients with liver cirrhosis HCV and HDV, where the virological response was absent, more severe and early complications of antiviral therapy are observed: the blood count shows anemia, major leukopenia and thrombocytopenia.</p></dc:description> <dc:description xml:lang='ru'><p>Группа исследования: 49 пациентов, 17 (34,69%) женщин и 32 (65,31%) мужчин с циррозом печени вирусной этиологии, стадия Child-Pugh А: 24 – вирусной этиологии D и 25 – вирусной этиологии C. Средний возраст: 44,41 ± 0,4 лет у женщин и 47,59 ± 0,6 лет у мужчин. Цель: оценка ответа на противовирусное лечение на 12-ой неделе и на 24-ой неделе после начала лечения и оценка лабораторных показателей во время противовирусной терапии у больных с циррозом печени С или D. У пациентов с циррозом печени HDV, леченных Peg-INF, была достигнута авиремия на 12-ой неделе в 28% случаев и на 24-ой неделе лечения – в 25% случаев. В группе пациентов с циррозом печени вирусной этиологии С, леченных Peg-INF + рибавирин, наблюдается на 12-ой неделе лечения положительный ответ у 75% пациентов: 48% достигнули полный ранний вирусологический ответ, 24% – частичный. Оценка противовирусного лечения через 24 недели после начала показала положительный вирусологический ответ в 56% случаев. У пациентов с циррозом печени вирусой этиологии С или D с отсутствием вирусологического ответа на противирусную терапию обнаруживаются осложнения более тяжелые и раньше: в анализе крови – анемия, лейкопения и тромбоцитопения.</p></dc:description> <dc:source>Sănătate Publică, Economie şi Management în Medicină 50 (5) 118-122</dc:source> <dc:subject>liver cirrhosis</dc:subject> <dc:subject>antiviral treatment</dc:subject> <dc:subject>sustained virological response</dc:subject> <dc:subject>unidentifi ed viremia</dc:subject> <dc:subject>цирроз печени</dc:subject> <dc:subject>противовирусное лечение</dc:subject> <dc:subject>вирусологический ответ</dc:subject> <dc:subject>авиремия</dc:subject> <dc:title>Evaluarea tratamentului antiviral la pacienţii cu ciroze hepatice de etiologie virală C şi D</dc:title> <dc:type>info:eu-repo/semantics/article</dc:type> </oai_dc:dc>
|
|
|
